Wire · operational-macro
FDA approves first drug, Infilbray, for neurological problems in Gaucher
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 19 November 2026 · Fusion42 review
The FDA approved Infilbray (venglustat), developed by Sanofi, as the first treatment targeting neurological symptoms of Gaucher disease type 3 for both adults and children. In clinical trials, Infilbray showed significant improvements in cognition and motor coordination while managing non-neurological symptoms as effectively as existing therapies.
This Wire brief sits within Fusion42's coverage of Biotech, and 7 sources have reported it between 18 Nov 2026 and 20 Nov 2026.
◆ ◆ The Wire takeaway
Neurological care for Gaucher type 3 just opened a new front. If you develop treatments for rare neurological diseases, this FDA approval signals a fresh competitive and partnership landscape.
◆ Coverage
7 sources · first reported 18 Nov 2026 · latest 20 Nov 2026
◆ Related on Wire
◆ Topics